NASDAQ:HGEN Humanigen (HGEN) Stock Forecast, Price & News $0.0091 0.00 (-8.08%) (As of 05:37 PM ET) Add Compare Share Share Today's Range$0.0090▼$0.0150-Day Range$0.01▼$0.2052-Week Range$0.01▼$0.26Volume681,124 shsAverage Volume2.94 million shsMarket Capitalization$1.08 millionP/E RatioN/ADividend YieldN/APrice Target$0.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Humanigen (NASDAQ:HGEN) StockHumanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.Read More HGEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HGEN Stock News HeadlinesAugust 11, 2023 | uk.finance.yahoo.comHumanigen, Inc. (HGEN) stock price, news, quote & history – Yahoo FinanceAugust 7, 2023 | finance.yahoo.comHumanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell TransplantationSeptember 27, 2023 | Chaikin Analytics (Ad)"This Could be the Biggest Stock Story of 2023"A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.July 30, 2023 | proactiveinvestors.comHumanigen stock removed from S&P Total Market Index as firm faces...July 28, 2023 | proactiveinvestors.comHumanigen stock removed from S&P Total Market Index as firm faces bankruptcyJuly 25, 2023 | marketwatch.comHumanigen Shares Plunge 73% as Business Combination Fails, Going Concern Issues RaisedJuly 25, 2023 | markets.businessinsider.comWhy Is Humanigen (HGEN) Stock Down 72% Today?July 25, 2023 | msn.comHumanigen (NASDAQ:HGEN) Nosedives with Bankruptcy Looming LargeSeptember 27, 2023 | Stansberry Research (Ad)A 73-Year-Old Market Signal With 95% Accuracy Just FlashedThis signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.July 25, 2023 | seekingalpha.comHumanigen to weigh bankruptcy as shares delist from NasdaqApril 17, 2023 | nasdaq.comHumanigen (HGEN) Surges on Lenzilumab Study Data for LeukemiaApril 14, 2023 | finance.yahoo.comHumanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of LeukemiaDecember 20, 2022 | finance.yahoo.comHumanigen, Inc. (HGEN) Stock Historical Prices & Data - Yahoo FinanceNovember 14, 2022 | finance.yahoo.comHumanigen Reports Third Quarter 2022 Financial ResultsNovember 10, 2022 | finance.yahoo.comHumanigen Announces Participation and Presentation at Jefferies London Healthcare ConferenceOctober 31, 2022 | finance.yahoo.comHumanigen Announces Retention of SC&H Capital as Financial AdvisorOctober 19, 2022 | stockhouse.com2022-10-19 | NDAQ:HGEN | Press Release | Humanigen Inc. - StockhouseOctober 19, 2022 | benzinga.comThis Addiction Drug Shows Some Potential Against Long COVID Symptoms - Humanigen (NASDAQ:HGEN), GSK (NYSE - BenzingaOctober 19, 2022 | benzinga.comCLASS ACTION UPDATE for HGEN, SQ and OPEN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Be - BenzingaOctober 18, 2022 | businesswire.comGLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action – HGEN - Business WireOctober 18, 2022 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action - HGENOctober 17, 2022 | gurufocus.comBragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm - GuruFocus.comOctober 16, 2022 | benzinga.comHGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Humanigen, Inc. Investors of a Class Action Lawsuit and Upc - BenzingaOctober 15, 2022 | stockhouse.com2022-10-15 | NDAQ:HGEN | Press Release | Humanigen Inc. - StockhouseOctober 14, 2022 | gurufocus.comHGEN SHAREHOLDER ALERT: Jakubo - GuruFocus.comOctober 14, 2022 | stockhouse.com2022-10-14 | NDAQ:HGEN | Press Release | Humanigen Inc. - StockhouseOctober 13, 2022 | gurufocus.comHGEN LAWSUIT ALERT: Levi & Kor - GuruFocus.comSee More Headlines Receive HGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter. Email Address HGEN Company Calendar Last Earnings11/12/2021Today9/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HGEN CUSIPN/A CIK1293310 Webwww.humanigen.com Phone650-243-3100FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Forecast$0.50 High Stock Price Forecast$0.50 Low Stock Price Forecast$0.50 Forecasted Upside/Downside+5,002.0%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,730,000.00 Net Margins-3,156.80% Pretax Margin-3,156.80% Return on EquityN/A Return on Assets-233.88% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09 Sales & Book Value Annual Sales$2.51 million Price / Sales0.46 Cash FlowN/A Price / Cash FlowN/A Book Value($0.45) per share Price / Book-0.02Miscellaneous Outstanding Shares119,080,000Free Float93,240,000Market Cap$1.17 million OptionableOptionable Beta-0.98 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Cameron Durrant M.D. (Age 63)MBA, Chairman, CEO & Acting CFO Comp: $640kDr. Dale Chappell M.B.A. (Age 53)M.D., MBA, Chief Scientific Officer & Director Comp: $410kMr. Edward P. Jordan M.B.A. (Age 55)Chief Commercial Officer Comp: $364.75kMr. Robert Atwill M.B.A.Sr. VP and Head of Asia-Pacific Region & Bus. Devel.Key CompetitorsClearmind MedicineNASDAQ:CMNDGalmed PharmaceuticalsNASDAQ:GLMDChina SXT PharmaceuticalsNASDAQ:SXTCChina PharmaNYSE:CPHINeptune Wellness SolutionsNASDAQ:NEPTView All Competitors HGEN Stock - Frequently Asked Questions Should I buy or sell Humanigen stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humanigen in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" HGEN shares. View HGEN analyst ratings or view top-rated stocks. What is Humanigen's stock price forecast for 2023? 2 Wall Street research analysts have issued 1 year target prices for Humanigen's shares. Their HGEN share price forecasts range from $0.50 to $0.50. On average, they expect the company's stock price to reach $0.50 in the next twelve months. This suggests a possible upside of 5,002.0% from the stock's current price. View analysts price targets for HGEN or view top-rated stocks among Wall Street analysts. How have HGEN shares performed in 2023? Humanigen's stock was trading at $0.12 at the start of the year. Since then, HGEN shares have decreased by 91.8% and is now trading at $0.0098. View the best growth stocks for 2023 here. How were Humanigen's earnings last quarter? Humanigen, Inc. (NASDAQ:HGEN) posted its earnings results on Friday, November, 12th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.14. The business had revenue of $1.04 million for the quarter, compared to the consensus estimate of $0.40 million. When did Humanigen's stock split? Humanigen's stock reverse split on the morning of Monday, September 14th 2020. The 1-5 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What is Humanigen's stock symbol? Humanigen trades on the NASDAQ under the ticker symbol "HGEN." How do I buy shares of Humanigen? Shares of HGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Humanigen's stock price today? One share of HGEN stock can currently be purchased for approximately $0.01. How much money does Humanigen make? Humanigen (NASDAQ:HGEN) has a market capitalization of $1.17 million and generates $2.51 million in revenue each year. The company earns $-70,730,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. How can I contact Humanigen? Humanigen's mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The official website for the company is www.humanigen.com. The company can be reached via phone at 650-243-3100 or via email at ir@humanigen.com. This page (NASDAQ:HGEN) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humanigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.